EchoCalc vs ESC CVD Risk Calculation Usage & Stats

EchoCalc provides access to all the key echocardiography reference data commonly used in clinical practice: - LV/RV size & function, LV mass, aortic dimensions, atrial dimensions - Diastolic function - Prosthetic aortic & mitral valve reference data - Topic guides on each chapter with how-to explanations on how to measure and interpret echo data - Updated to the latest BSE reference data but also allows switching to ASE/EACVI references - Access to a mobile-friendly version of all recent BSE guidelines: - Standard TTE Study - Standard TOE Study - Outpatient Indications - Inpatient Indications - Aortic Stenosis - Aortic Regurgitation - Mitral Valve - Tricuspid & Pulmonary Valves - Right Heart - Pulmonary Hypertension - Diastolic Dysfunction - Cardio-Oncology - Hypertrophic Cardiomyopathy - Valve Replacement - Stress Echo - Restrictive Cardiomyopathy - ARVC - Marfan Syndrome - Congenital

Apple App ストア
無料
医学

ストアランキング

- -

ESC CVD Risk Calculation

The ESC CVD Risk Calculation App is designed for healthcare professionals. It provides calculators assessing individual cardiovascular risk. It includes calculators for primary and secondary prevention in various populations: 1. SCORE2 2. SCORE2-OP 3. SCORE2-Diabetes 4. ASCVD 5. SMART 6. SMART-REACH* 7. DIAL* 8. LIFE-CVD* * Available online on U-Prevent (Internet connection required) The ESC CVD Risk Calculation App is available in English. It provides guidance to the most adapted calculator for your patient, and provides an estimation of cardiovascular risk. Of note, patient data are not stored in the App. This application is only for informative use and is not intended to provide therapeutic support or diagnosis assistance. This Application is powered by the European Society of Cardiology (ESC), based upon the source codes of the U-Prevent webtool, a concept developed by University Medical Center Utrecht, redesigned and owned by ORTEC. The SCORE2, SCORE2-OP and SCORE2-Diabetes calculators were developed in collaboration with the ESC Cardiovascular Risk Collaboration unit. The Application has recently been updated in the framework of the EAPC IMPLEMENT Programme (2023) which was supported by Novo Nordisk in the form of an educational grant. The sponsor did not have any involvement or influence on the features nor on the scientific content within the Application.